Literature DB >> 10469160

The tumour microcirculation as a target in cancer therapy: a clearer perspective.

J Denekamp1.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10469160     DOI： 10.1046/j.1365-2362.1999.00558.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN： 0014-2972            Impact factor:   4.686


× No keyword cloud information.
  9 in total

1.  Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Authors:  Lori Rice; Christine Pampo; Sharon Lepler; Amyn M Rojiani; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2010-10-23       Impact factor: 3.514

2.  Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer.

Authors:  Shifalika Tangutoori; Bryan Q Spring; Zhiming Mai; Akilan Palanisami; Lawrence B Mensah; Tayyaba Hasan
Journal:  Nanomedicine       Date:  2015-09-25       Impact factor: 5.307

3.  Phase I clinical study of vascular targeting fluorescent cationic liposomes in head and neck cancer.

Authors:  Sebastian Strieth; Christoph Dunau; Kristina Kolbow; Ruth Knuechel; Uwe Michaelis; Hannelore Ledderose; Martin E Eichhorn; Donata Strelczyk; Uta Tschiesner; Barbara Wollenberg; Marc Dellian
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-27       Impact factor: 2.503

4.  In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503.

Authors:  Mamta Wankhede; Casey Dedeugd; Dietmar W Siemann; Brian S Sorg
Journal:  Oncol Rep       Date:  2010-03       Impact factor: 3.906

5.  The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

Authors:  Chryso Kanthou; Olga Greco; Anna Stratford; Ian Cook; Richard Knight; Omar Benzakour; Gillian Tozer
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

6.  Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients.

Authors:  Eline Abma; Emmelie Stock; Ward De Spiegelaere; Leen Van Brantegem; Katrien Vanderperren; Yicheng Ni; Matthijs Vynck; Sylvie Daminet; Kaat De Clercq; Hilde de Rooster
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

7.  Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.

Authors:  W Shi; D W Siemann
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

8.  An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.

Authors:  H Murakami; T Kurata; Y Onozawa; J Watanabe; A Ono; T Takahashi; N Yamamoto; Y Fujisaka; H Kiyota; H Hayashi; K Tanaka; K Nakagawa; S Kuroda
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-30       Impact factor: 3.333

9.  Effective Delivery of Anti-Cancer Drug Molecules with Shape Transforming Liquid Metal Particles.

Authors:  Dasom Kim; Jangsun Hwang; Yonghyun Choi; Yejin Kwon; Jaehee Jang; Semi Yoon; Jonghoon Choi
Journal:  Cancers (Basel)       Date:  2019-10-27       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.